drugset / Trial / NCT07244666
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
Phase 0
Not yet recruiting
36 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Leman Biotech Co., Ltd. · collab
NaSequentialOpen-labelTreatment
Summary
A Study of Metabolically Armed EGFRvII CAR-T Cells Therapy for Patients With Recurrent Glioblastoma
Timeline
- Start
- 2025-11-15
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meta10-EGFRvIII | Cell therapy | — | Intravenous |